The induction of a strong cytotoxic T cell response is an important prerequisite for successful immunotherapy against many viral diseases and tumors. Nucleotide vaccines, including mRNA vaccines with their intracellular antigen synthesis, have been shown to be potent activators of a cytotoxic immune response. The intracellular delivery of mRNA vaccines to the cytosol of antigen presenting immune cells is still not sufficiently well understood. Here, we report on the development of a lipid nanoparticle formulation for the delivery of mRNA vaccines to induce a cytotoxic CD 8 T cell response. We show transfection of dendritic cells, macrophages, and neutrophils. The efficacy of the vaccine was tested in an aggressive B16F10 melanoma model. We found a strong CD 8 T cell activation after a single immunization. Treatment of B16F10 melanoma tumors with lipid nanoparticles containing mRNA coding for the tumor-associated antigens gp100 and TRP2 resulted in tumor shrinkage, and extended the overall survival of the treated mice. The immune response can be further increased by the incorporation of the adjuvant LPS. In conclusion, the lipid nanoparticle formulation presented here is a promising vector for mRNA vaccine delivery, one that is capable of inducing a strong cytotoxic T cell response.
Further optimization, including the incorporation of different adjuvants, will likely enhance the potency of the vaccine. 5 We hypothesized that LNPs from this library can be optimized for mRNA vaccine delivery for induction of a potent CD 8 T cell immune response.
To test the potential of expanding antigen specific T cell populations, there is no adequate in vitro assay. This follows because both T cell counts and antibody titers are 'second-order' effects that do not just depend on transfection efficiency of a particular type of immune cell, but also on the complex immunological signaling cascade which is necessary for an immune response to take place. Accordingly, a library of LNP formulations was optimized to induce a potent T cell response in vivo. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 We developed an optimized LNP library complexed with mRNA coding for the model immunology protein ovalbumin (OVA) in groups of five C57BL/6 mice by subcutaneous injection in the lower back (dorsal posterior) at a dose of 10 µg of mRNA per mouse ( Figure   1A -C). In the first phase of the optimization (Library A), we tested different lipids for the individual components: ionizable lipid, phospholipid, cholesterol, PEGylated lipid, and additive at a constant molar ratio ( Table 1) . The mice were bled seven days after a single injection, the red blood cells were lysed, and the monocytes were stained using a tetramer conjugate for the OVA-epitope SIINFEKL to determine the percentage of OVA specific CD8 T cells ( Figure 1D) .
A list of the tested formulations and the corresponding CD 8 T cells levels are provided in the (Table S1) . Among the ionizable lipids tested: C12-200, cKK-E12, 503O13, DOTAP, and DODAP, only cKK-E12 performed better than in the original formulation. 32 The two phospholipids (DSPC and DOPS), out of the six tested, performed better than DOPE did in the original formulation. However, using either phospholipid, 5 to 10 days after the immunization, more than 20% of the mice tested developed inflammation at the injection site. For this reason, we stopped using DSPC and DOPS. Formulations without phospholipid did not perform well at all: ( Figure 1D , Formulation A-1). We also replaced cholesterol with DC-cholesterol, because it has been successfully used to formulate lipid nanoparticles for DNA plasmid and siRNA delivery. 33 However, we did not observe a higher percentage of OVA-specific CD 8 T cells using DC-cholesterol. By testing different PEG chain lengths, we found that the PEG length as well as the anchor lipid greatly influence the LNP diameter: C14-PEG350 (232nm), C14-PEG1000 (121nm), C14-PEG2000 (67nm), C18-PEG2000 (110nm), C14-PEG3000 (96nm), with the smallest LNP, C14-PEG2000, yielding the highest T cell levels. Arachidonic acid has been used to deliver LNPs carrying mRNA coding for Cas9. 34 However, in the case of vaccines, removal of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   8   the arachidonic acid additive almost tripled the CD 8 T cell count. Interestingly, the SLS additive   performed better than the no additive case. Based on the Library A screening, we identified   cKK-E12 from formulation A-2, C14-PEG2000 from formulation A-12, and SLS from formulation A-18 as promising components for further investigation in Library B. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 In the second phase of the optimization (Library B), we combined the different individual components that we identified in the first phase as being beneficial (Library A), and investigated the effect of altering the molar compositions of the components. We found that varying the molar composition of cKK-E12 correlated with detected CD8 T cell levels. Lower molar compositions of cKK-E12 led to increased T cell levels until 10 mol%, beyond which the deviation around the mean concentration of antigen specific CD 8 T cell levels increased significantly. (Figure S1 )
The particle sizes in the tested formulations ranged between 50nm and 150nm. In this particle size range, we could not establish a correlation between particle size and CD 8 T cell expansion ( Figure S3A ). The measured formulations had a negative zeta potential, and the highest CD 8 T cell expansions were observed with formulations having zeta potentials between -15 mV to -3 mV ( Figure S3B) . For either the molar compositions of DOPE and Cholesterol, we found no clear correlations between their molar compositions and the number of CD 8 T cells present. We then decided to further investigate the properties of formulation B-11 yielding the highest CD 8
T cell levels. To evaluate the locations of mRNA transfection and protein synthesis, we formulated firefly luciferase (FFL) mRNA in B-11 LNPs, and injected 10 µg of mRNA per mouse, as used in the vaccine study. 24 hours later, we used bioluminescence to detect the location of protein expression (Figure 2A) . We found FFL expressed at the injection site and in the draining lymph nodes, in the inguinal lymph nodes, as well as in some axillary lymph nodes.
Luminescence was not detected in the liver, spleen, lung, or intestines. We then monitored the protein expression of the 3 formulations A-1, A-6, and B-11 at the injection site over time ( Figure 2B and C) . It is noteworthy that all three formulations reached the expression maximum of about four orders of magnitude after 24 hours, and declined slowly afterwards. Formulation B-11 that elicited the highest CD 8 T cell levels did not translate into a higher maximal FFL concentration, compared to the other two formulations, but exhibited less drop-off in FFL concentration. All three formulations produced FFL for at least 10 days. The injection of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 same amount of unformulated mRNA led to an increase of one order of magnitude and dropped off rapidly. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 To determine whether we are transfecting APCs, we used the Ai14D reporter mouse and LNPs containing mRNA coding for Cre-recombinase ( Figure 2D) . These mice harbor a mutation in the Gt(ROSA)26Sor locus with a loxP-flanked STOP cassette preventing transcription of a CAG 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 promoter driven tdTomato red fluorescent protein. Cells express tdTomato upon Cre-mediated recombination. 35 We have chosen the Ai14D reporter mouse because expression levels using commercially available mRNA coding for fluorescent proteins, such as GFP, toTomato, or cyan fluorescent protein, were below the detection levels for analysis using flow cytometry. The draining lymph nodes, the inguinal lymph nodes in this case were removed, digested, and the monocytes were stained with secondary antibodies. Flow cytometry revealed that 4.6% of DCs, 1.2% of macrophages, 3.3% of neutrophiles, and 0.06% of B cells expressed the Crerecombinase.
Unmodified RNA has the potential to activate endosomal Toll-like receptors 3 (TLR3), TLR7, and TLR8. 36 Activation of these receptors induces an inflammatory response, transcription of pro-inflammatory cytokines, as well as up-regulation of chemokines and type I interferons. This effect is desirable for vaccine application, and activation of the immune system is necessary to initiate an immune response. However, other cytoplasmatic RNA sensors, such as cytoplasmic retinoic acid-inducible gene I (RIG-I) or protein kinase RNA-activated (PKR), may hinder translation and enhance RNA degradation. 8, 37 In contrast to the immune activation, this effect of unmodified mRNA would be counter-productive for a strong immune response. Karikó et al. showed that by incorporating naturally occurring modified nucleosides, such as 5methylcytidine, 5-methyluridine, 2-thiouridine, or pseudouridine, activation of the pattern recognition receptors can be suppressed. 38 We then compared the capacity of modified and unmodified mRNA formulations to elicit CD8 and CD4 T cell proliferations in vivo. We measured the CD8 and CD4 T cell levels in blood, six to eleven days after immunization, of mRNA coding for OVA unmodified and mRNA with the same nucleotide sequence, fully substituted with pseudouridine and 5-methylcytidine (Figure 3A and 3B ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Cox test. The two mRNA treated groups are not significantly different). (F) The percentage of SIINFEKL specific CD 8 T cells that were analyzed on day 17, the difference in CD 8 T cells was not statistically significant. vaccines. 20, 21 Both studies suggest that type I interferon is necessary for a protective CD8 T cell response. We also measured the antigen specific IgG titers 7 weeks after a single immunization ( Figure S2) . Only at a serum dilution of 1:16 or smaller, OVA specific IgG serum antibody titers were more than a standard deviation different from those in the control mice that were immunized with LNPs containing an irrelevant control mRNA.
To address the functionality of the proliferated CD 8 T cells, we tested formulation B-11 in a transgenic OVA-expressing tumor immunotherapy model to evaluate whether proliferated CD 8
T cells induce potent antitumor function. To this end, we injected mice with 10 5 of B16-OVA 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 melanoma cells, and began treatment on day 3 after tumor inoculation, when tumors were visible and palpable in all mice. The treatment consisted of a total of 3 injections of either modified or unmodified OVA mRNA LNPs (10 µg of mRNA per mouse per injection) in formulation B-11.
We decided to choose a dosing schedule similar to what has been published by the mRNA company CureVac. For therapeutic cancer immunotherapy applications they dosed successfully in 3 to 4 day intervals. 39 We treated the mice on days 3, 6, and 10 and compared them against an untreated control group (Figure 3D) . Mice treated with either modified or unmodified mRNA LNPs had slower tumor growth and even tumor shrinkage for up to 7 days after the last treatment. We measured the CD 8 T cell levels seven days after the last treatment, and found them to be higher for the group treated with LNPs containing unmodified mRNA (Figure 3F) .
To test our formulations with antigens other than OVA, we investigated the B16F10 melanoma model and encapsulating mRNA encoding for two well described and widely studied melanoma self-antigens: tyrosinase-related protein 2 (TRP2) 40 and a point-mutated version of glycoprotein 100 (gp100) 41 . In this version of gp100, the serine in position 27 is exchanged to a proline. We chose self-antigens because it has been shown that overcoming self-tolerance can be very difficult, and we hypothesized that our formulation would be potent enough to overcome that. 42 Nano Letters   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 lipoplex. 20 The untreated and irrelevant control mRNA mice all died within three weeks. ( Figure   4B ) All 3 treatment groups resulted in longer overall survivals: mice treated with either gp100, TRP2, and mice treated 3 times with TRP2, followed by 3 times with gp100. One mouse in the latter group survived for 60 days until the end of the study without any visible tumors.
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We then tested the hypothesis if enhanced TLR activation could increase the potency of the immune response by incorporating an adjuvant in the LNP formulation. We replaced 1% of the molar composition of PEG in the optimized LNP formulation with lipopolysaccharide (LPS, 10 µg per mL), consisting of a lipid A anchor, an inner core, an outer core, and an O-antigen repeat. 44 LPS is a very potent TLR4 agonist. 45 We envisioned that the LPS anchors in the outer membrane of the LNPs via the lipid A anchor, and points the highly hydrophobic O-antigen repeat outward. An additional benefit of replacing some of the shielding PEG with O-antigen repeat carbohydrates may be that the LNPs bind to APCs via carbohydrate recognizing lectin receptors that are omnipresent on APCs and are endocytosed more efficiently. 18 Dendritic cells express a number of lectins on their surfaces that allow ligand capture and endocytosis. These include the mannose receptor 46 , Langerin also known as CD207 47 , Dec-205 48 , DC-SIGN also 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   20 known as CD209 49 , Dectin-1, and Dectin-2. 50 The CD 4 T cell kinetics was not different from those observed in either treatment group. (Figure S4 ) The observed CD 8 T cell levels peaked one day after the non-LPS LNPs on day 8 at 6.3% antigen specific CD 8 T cells. (Figure 5A ) It is noteworthy that LPS-containing LNPs may induce local inflammation at LPS concentrations of more than 1.0 µg per mouse. We then added LPS to LNPs containing TRP2 mRNA, and tested them in the B16F10 melanoma model. We found that the mice receiving the LPS containing TRP2 mRNA LNPs survived significantly longer compared to the controls and mice receiving TRP2 mRNA LNPs. (Figure 5B and 5C) A. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 mRNA was used as the irrelevant control for the studies reported in Figure 5 ).
Days after Tumor Innoculation
In conclusion, we presented evidence that our optimized LNP formulation, B-11, works well for delivering mRNA vaccines. Using the Ai14D reporter mice and the B-11 LNP formulation, we showed transfection in different immune cell populations, including dendritic cells, macrophages, neutrophils, and B cells. Cytosolic antigen synthesis and degradation by the proteasome enables antigen presentation on MHC-I, and consequently, activation of a potent CD 8 T cell response. We did not only induce CD 8 T cell proliferation, but the killer cells were also functional, as shown by extending the overall survival in a transgenic mouse melanoma model.
Even more exciting was the effect on the aggressive B16F10 tumor model, where mRNA coding for the tumor associated self-antigens, TRP2 and gp100, was able to overcome the self-tolerance and to significantly extend the overall mice survival. The fact that adding LPS to the LNP 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 formulation further increased survival is an indication that such additions may increase the potency of mRNA vaccines delivered by LNPs. The proof of concept presented here warrants further investigation of LNPs as potentially useful mRNA vaccine vectors Materials and Methods. Lipid Nanoparticle (LNP) Synthesis. LNPs were synthesized by mixing an aqueous phase containing the mRNA with an ethanol phase containing the lipids in a microfluidic chip device as described previously. 51 Briefly, the aqueous phase was prepared in cKK-E12 (prepared as previously described 32 ), 503O13 (prepared as previously described 52 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 LNP Characterization. The size and polydispersity index (PDI) of the LNPs were measured using dynamic light scattering in 1X PBS (ZetaPALS, Brookhaven Instruments) ( Table 2) . Zeta potentials were measured using the same instrument in a 0.1X PBS solution. Diameters are reported as the largest intensity mean peak average, which constitutes >95% of the nanoparticles present in the sample. To calculate the nucleic acid encapsulation efficiency, a modified Quant-iT RiboGreen RNA assay (Invitrogen) was used as previously described. 53 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 µL of the LNP solution was dropped on a lacey copper grid coated with a continuous carbon film and blotted to remove excess sample without damaging the carbon layer by Gatan Cryo Plunge III. A grid was mounted on a Gatan 626 single tilt cryo-holder equipped in the TEM column. The specimen and holder tip were cooled down by liquid nitrogen during transfer into the microscope and subsequent imaging. Imaging on a JEOL 2100 FEG microscope was done using minimum dose method. This is essential to avoid sample damage under the electron beam. The microscope was operated at 200 kV, and with a magnification in the range of 10 000∼60 000 to assess particle diameter and distribution. All images were recorded on a Gatan 2kx2k UltraScan CCD camera.
Mice. All procedures were performed under an animal protocol approved by the Massachusetts Institute of Technology Committee on Animal Care (CAC), and in accordance with the guidelines for animal care in a MIT animal facility. C57BL/6J mice and B6.Cg- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Gt(ROSA) 26Sortm14(CAG-tdTomato)Hze /J (Ai14D) mice, 6 to 8 weeks of age, were purchased from Jackson Laboratories and housed in an MIT animal facility.
Immunization. Mice were anesthetized in a ventilated anesthesia chamber with 2.5% isofluorane in oxygen. The lower back of the mice were shaved with a clipper and the LNPs (0.1 mL containing 10 µg of mRNA per mouse) were injected subcutaneously in the lower back of the mice. Mice were put back in their cages, and monitored for signs of distress and local inflammation at the injection site.
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